Elicio Therapeutics (ELTX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1.78, -0.56% vs the prior close of $1.79.
- Volume 169.40K shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ELTX dips 0.6% to $1.78. Closed at $1.78, -0.56% vs the prior close of $1.79. Day range $1.76–$1.86, opened at $1.78.
ELTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ELTX dips 0.6% to $1.78
- Closed at $1.78, -0.56% vs the prior close of $1.79. Day range $1.76–$1.86, opened at $1.78.
- Volume was 169.40K shares, 0.6x its 50-day average of 304.32K — lighter than usual.
- Price is -24.7% vs its 50-day average ($2.36) and -75.0% vs its 200-day average ($7.13).
- 52-week range $1.71–$16.00; today's close sits at 1% of that range, 88.9% below the 52-week high.
Oct 14, 2026 — ELTX rises 1.1% to $1.79
- Closed at $1.79, +1.13% vs the prior close of $1.77. Day range $1.75–$1.91, opened at $1.77.
- Volume was 373.30K shares, 1.2x its 50-day average of 310.71K.
- Price is -25.1% vs its 50-day average ($2.39) and -75.0% vs its 200-day average ($7.16).
- 52-week range $1.71–$16.00; today's close sits at 1% of that range, 88.8% below the 52-week high.
Oct 13, 2026 — ELTX slides 5.9% to $1.77
- Closed at $1.77, -5.85% vs the prior close of $1.88. Day range $1.73–$1.88, opened at $1.88.
- Volume was 232.00K shares, 0.7x its 50-day average of 311.93K.
- Price is -26.8% vs its 50-day average ($2.42) and -75.4% vs its 200-day average ($7.19).
- 52-week range $1.71–$16.00; today's close sits at 0% of that range, 88.9% below the 52-week high.
Oct 12, 2026 — ELTX dips 0.5% to $1.88
- Closed at $1.88, -0.53% vs the prior close of $1.89. Day range $1.82–$1.91, opened at $1.90.
- Volume was 164.40K shares, 0.5x its 50-day average of 316.78K — lighter than usual.
- Price is -23.0% vs its 50-day average ($2.44) and -74.0% vs its 200-day average ($7.22).
- 52-week range $1.71–$16.00; today's close sits at 1% of that range, 88.3% below the 52-week high.
Oct 9, 2026 — ELTX jumps 4.4% to $1.89
- Closed at $1.89, +4.42% vs the prior close of $1.81. Day range $1.78–$1.92, opened at $1.83.
- Volume was 306.20K shares, 1.0x its 50-day average of 314.22K.
- Price is -23.1% vs its 50-day average ($2.46) and -73.9% vs its 200-day average ($7.25).
- 52-week range $1.71–$16.00; today's close sits at 1% of that range, 88.2% below the 52-week high.
- SEC filings that day: DEF 14A.
Oct 8, 2026 — ELTX dips 2.2% to $1.81, 5 down days in a row
- Closed at $1.81, -2.16% vs the prior close of $1.85. Day range $1.74–$1.85, opened at $1.85.
- Volume was 267.00K shares, 0.9x its 50-day average of 314.08K.
- Price is -27.0% vs its 50-day average ($2.48) and -75.1% vs its 200-day average ($7.28).
- 52-week range $1.71–$16.00; today's close sits at 1% of that range, 88.7% below the 52-week high.
- That makes 5 straight losses.
Oct 7, 2026 — ELTX dips 1.6% to $1.85, 4 down days in a row
- Closed at $1.85, -1.60% vs the prior close of $1.88. Day range $1.83–$1.92, opened at $1.87.
- Volume was 138.90K shares, 0.4x its 50-day average of 318.53K — lighter than usual.
- Price is -26.0% vs its 50-day average ($2.50) and -74.7% vs its 200-day average ($7.31).
- 52-week range $1.71–$16.00; today's close sits at 1% of that range, 88.4% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — ELTX dips 2.1% to $1.88, 3 down days in a row
- Closed at $1.88, -2.08% vs the prior close of $1.92. Day range $1.86–$1.96, opened at $1.90.
- Volume was 259.10K shares, 0.8x its 50-day average of 318.45K.
- Price is -25.5% vs its 50-day average ($2.52) and -74.4% vs its 200-day average ($7.34).
- 52-week range $1.71–$16.00; today's close sits at 1% of that range, 88.3% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — ELTX ends flat (+0.0%) to $1.92
- Closed at $1.92, +0.00% vs the prior close of $1.92. Day range $1.81–$1.96, opened at $1.93.
- Volume was 200.20K shares, 0.6x its 50-day average of 319.39K.
- Price is -24.6% vs its 50-day average ($2.55) and -74.0% vs its 200-day average ($7.37).
- 52-week range $1.71–$16.00; today's close sits at 2% of that range, 88.0% below the 52-week high.
Oct 2, 2026 — ELTX ends flat (+0.0%) to $1.92
- Closed at $1.92, +0.00% vs the prior close of $1.92. Day range $1.85–$1.97, opened at $1.95.
- Volume was 175.90K shares, 0.5x its 50-day average of 321.01K — lighter than usual.
- Price is -25.2% vs its 50-day average ($2.57) and -74.1% vs its 200-day average ($7.41).
- 52-week range $1.71–$16.00; today's close sits at 2% of that range, 88.0% below the 52-week high.
ELTX latest news & SEC filings
Every SEC filing by or about ELTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Sep 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.08 — Set shareholder nomination dates.
- Item 8.01 — Reported other events the company considers important.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$8.22M (prior year -$10.56M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.43 (prior year -$0.66) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 16, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 8.01 — Reported other events the company considers important.
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade ELTX
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Mar 12, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.66% (largest 5.9%).
- Liquidity: about 291.08K shares (≈$518.12K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.78 vs a range of $1.71–$16.00 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 14, 2026; 10-Q Aug 13, 2026; 8-K Aug 13, 2026.
- Share count: 26.28M shares outstanding (Aug 11, 2026), +60.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ELTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1.78 | 1.86 | 1.76 | 1.78 | 169.40K |
| Oct 14, 2026 | 1.77 | 1.91 | 1.75 | 1.79 | 373.30K |
| Oct 13, 2026 | 1.88 | 1.88 | 1.73 | 1.77 | 232.00K |
| Oct 12, 2026 | 1.90 | 1.91 | 1.82 | 1.88 | 164.40K |
| Oct 9, 2026 | 1.83 | 1.92 | 1.78 | 1.89 | 306.20K |
| Oct 8, 2026 | 1.85 | 1.85 | 1.74 | 1.81 | 267.00K |
| Oct 7, 2026 | 1.87 | 1.92 | 1.83 | 1.85 | 138.90K |
| Oct 6, 2026 | 1.90 | 1.96 | 1.86 | 1.88 | 259.10K |
| Oct 5, 2026 | 1.93 | 1.96 | 1.81 | 1.92 | 200.20K |
| Oct 2, 2026 | 1.95 | 1.97 | 1.85 | 1.92 | 175.90K |
| Oct 1, 2026 | 1.82 | 1.96 | 1.82 | 1.92 | 310.20K |
| Sep 30, 2026 | 1.86 | 1.86 | 1.78 | 1.82 | 274.00K |
| Sep 29, 2026 | 1.85 | 1.90 | 1.77 | 1.84 | 452.50K |
| Sep 28, 2026 | 1.85 | 1.90 | 1.81 | 1.85 | 222.10K |
| Sep 25, 2026 | 1.88 | 1.90 | 1.82 | 1.84 | 165.40K |
| Sep 24, 2026 | 1.88 | 2.00 | 1.81 | 1.88 | 339.70K |
| Sep 23, 2026 | 1.87 | 1.89 | 1.84 | 1.87 | 195.40K |
| Sep 22, 2026 | 1.92 | 1.92 | 1.82 | 1.87 | 402.60K |
| Sep 21, 2026 | 1.92 | 2.02 | 1.91 | 1.91 | 483.60K |
| Sep 18, 2026 | 1.86 | 2.00 | 1.86 | 1.89 | 689.70K |
About Elicio Therapeutics
Elicio Therapeutics (ELTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1601485.
ELTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Julian Adams | Director | Sep 2, 2026 |
| Carol Gail Ashe | Director | Sep 2, 2026 |
| Yekaterina Chudnovsky | Director | Sep 2, 2026 |
| Robert Connelly | CEO, President and Director | Jul 17, 2026 |
| Allen Nissenson | Director | Sep 2, 2026 |
| Robert R Ruffolo | Director | Sep 2, 2026 |
| Jay Venkatesan | Director | Sep 2, 2026 |
| Karen J Wilson | Director | Sep 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert Connelly | CEO, President and Director | Jul 17, 2026 |
| Peter Demuth | Chief Scientific Officer | Jul 17, 2026 |
| Christopher Haqq | See Remarks | Jul 17, 2026 |
| Preetam Shah | See Remarks | Jul 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
ELTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-39.57M | -2.58 | $-36.95M |
| Dec 31, 2024 | — | $-51.90M | -4.25 | $-37.07M |
| Dec 31, 2023 | — | $-35.20M | -6.96 | $-32.69M |
| Dec 31, 2022 | $2.30M | $-28.21M | -89.27 | $-22.18M |
| Dec 31, 2021 | $28.31M | $-54.57M | -1.93 | $-52.64M |
Latest balance sheet: total assets $31.33M, total liabilities $23.39M, cash $23.48M (as of Jun 30, 2026).
ELTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $3.15 |
| May 11, 2026 | 8-K Item 2.02 (results) | $11.61 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $10.90 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $9.11 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $9.07 |
| May 13, 2025 | 8-K Item 2.02 (results) | $5.71 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $6.16 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $5.20 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Mar 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ELTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.